Definium Therapeutics, Inc. (DFTX)
| Market Cap | 5.23B +636.1% |
| Revenue (ttm) | n/a |
| Net Income | -353.79M |
| EPS | -3.48 |
| Shares Out | 134.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,754,305 |
| Open | 37.73 |
| Previous Close | 37.73 |
| Day's Range | 37.73 - 39.37 |
| 52-Week Range | 8.77 - 49.70 |
| Beta | 2.24 |
| Analysts | Strong Buy |
| Price Target | 67.47 (+73.49%) |
| Earnings Date | Nov 2, 2026 |
About DFTX
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company’s lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Defi... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for DFTX stock is "Strong Buy." The 12-month stock price target is $67.47, which is an increase of 73.49% from the latest price.
News
Definium Therapeutics announce six poster presentations at Psych Congress
Definium Therapeutics (DFTX) announced six poster presentations at the Psych Congress taking place September 15 through 19 in New Orleans, LA. “This year at Psych Congress, we will share clinical…
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address un...
Definium Therapeutics receives Breakthrough Therapy designation for DT120 ODT
Definium Therapeutics (DFTX) announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy designation for DT120 Orally Disintegrating Tablet, ODT. The designation was su...
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address un...
Definium Therapeutics, Inc. put volume heavy and directionally bearish
Bearish flow noted in Definium Therapeutics (DFTX), Inc. with 1,463 puts trading, or 3x expected. Most active are Oct-26 37 puts and Oct-26 49 calls, with total volume in those…
Definium Therapeutics Announces New Employee Inducement Grants
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address un...
Definium Therapeutics, Inc. put volume heavy and directionally bearish
Bearish flow noted in Definium Therapeutics (DFTX), Inc. with 2,903 puts trading, or 6x expected. Most active are Oct-26 37 puts and Oct-26 50 calls, with total volume in those…
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intende...
Definium Therapeutics initiated with a Buy at BofA
BofA analyst Tazeen Ahmad initiated coverage of Definium Therapeutics (DFTX) with a Buy rating and $75 price target The company’s lead asset, DT120 – LSD – is in pivotal studies…
Definium Therapeutics announces results from Phase 3 study of DT120
Definium Therapeutics (DFTX) announced positive topline results from Voyage, its first Phase 3 study of DT120 Orally Disintegrating Tablet, ODT, 100 microgram in adults with generalized anxiety disord...
Definium Therapeutics price target raised to $70 from $60 at Oppenheimer
Oppenheimer raised the firm’s price target on Definium Therapeutics (DFTX) to $70 from $60 and keeps an Outperform rating on the shares.
Definium Therapeutics price target raised to $66 from $50 at Needham
Needham raised the firm’s price target on Definium Therapeutics (DFTX) to $66 from $50 and keeps a Buy rating on the shares.
RBC Capital boosts Definium price target, says opportunity will be robust
RBC Capital raised the firm’s price target on Definium Therapeutics (DFTX) to $66 from $57 and keeps an Outperform rating on the shares following “strong” Voyage study data. While RBC…
Definium Therapeutics price target raised to $75 from $57 at Baird
Baird raised the firm’s price target on Definium Therapeutics (DFTX) to $75 from $57 and keeps an Outperform rating on the shares. The firm updated its model following positive results…
Definium Therapeutics price target raised to $64 from $58 at Canaccord
Canaccord analyst Sumant Kulkarni raised the firm’s price target on Definium Therapeutics (DFTX) to $64 from $58 and keeps a Buy rating on the shares. The firm updated its model…
Definium Therapeutics price target raised to $90 from $74 at Jones
Jones raised the firm’s price target on Definium Therapeutics (DFTX) to $90 from $74 and keeps a Buy rating on the shares. The company announced that the Phase III VOYAGE…
Definium Therapeutics price target raised to $66 from $57 at RBC Capital
RBC Capital raised the firm’s price target on Definium Therapeutics (DFTX) to $66 from $57 and keeps an Outperform rating on the shares. Following the company’s call with more details,…
Definium Therapeutics price target raised to $55 from $50 at Maxim
Maxim raised the firm’s price target on Definium Therapeutics (DFTX) to $55 from $50 and keeps a Buy rating on the shares. The firm cites the company having announced topline…
Definium Therapeutics Slides: Corporate presentation
Definium Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
Definium Therapeutics Transcript: Study result
The phase III Voyage study of DT120 in GAD met all primary and key secondary endpoints, showing rapid, robust, and durable efficacy with a large effect size and favorable safety profile. Benefits were consistent across subgroups, and long-term data support sustained improvement with intermittent dosing.
Definium Therapeutics Press release: Study result
Definium Therapeutics issued a press release on August 12, 2026, disclosing material business information to investors.
Definium Therapeutics Slides: Study result
Definium Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intende...
Definium Therapeutics Earnings Call Transcript: Q2 2026
Phase III results for DT120 ODT in MDD showed unprecedented efficacy and tolerability, with pivotal GAD data imminent. Strong financials, including $1.1B in cash, support ongoing R&D and commercial launch preparations, positioning the company for long-term growth.
Definium Therapeutics Earnings release: Q2 2026
Definium Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.